Literature DB >> 10683199

Cholecystokinin-8 enhances nerve growth factor synthesis and promotes recovery of capsaicin-induced sensory deficit.

L Manni1, T Lundeberg, P Tirassa, L Aloe.   

Abstract

Alterations of nerve growth factor (NGF) expression have been demonstrated during peripheral nerve disease and the impaired expression or synthesis and transportation of NGF has been correlated with the pathogenesis of several peripheral neuropathies. Since exogenous NGF administration seems to cause undesired side-effects, therapeutical strategies based on the regulation of endogenous synthesis of NGF could prove useful in the clinical treatment of these disorders. The aim of the present study was to analyse the effects of exogenous peripheral administration of the neuropeptide cholecystokinin-8 (CCK-8) on endogenous NGF synthesis, NGF mRNA and distribution of peripheral neuropeptides which are known to be regulated by this neurotrophin. To address these questions we studied the effects of capsaicin (CAPS) before and after the administration of CCK-8 on NGF levels, NGF mRNA expression and localization, and the concentration of substance P (SP) and calcitonin gene-related peptide (CGRP) in peripheral tissue These studies demonstrate that administration of the CCK-8 induces an increase of NGF protein and mRNA in peripheral tissue. NGF level in paw skin of CAPS/CCK-8-treated mice is 3 fold higher than in controls (1241+/-110 pg gr(-1) of tissue wet weight versus 414+/-110 pg gr(-1) of controls) and nearly 6 fold higher than in CAPS-treated mice (1241+/-110 pg gr(-1) versus 248+/-27 pg gr(-1)). The increase of NGF is correlated with the recovery of impaired nocifensive behaviour and with an overexpression of SP and CGRP. The evidence that CCK-8 promotes the recovery of sensory deficits suggests a potential clinical use for this neuropeptide in peripheral neuropathies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683199      PMCID: PMC1571882          DOI: 10.1038/sj.bjp.0703088

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

Review 1.  Diabetic peripheral neuropathy.

Authors:  D S Younger; G Rosoklija; A P Hays
Journal:  Semin Neurol       Date:  1998       Impact factor: 3.420

2.  Expression of mRNAs for neurotrophins (NGF, BDNF, and NT-3) and their receptors (p75NGFR, trk, trkB, and trkC) in human peripheral neuropathies.

Authors:  G Sobue; M Yamamoto; M Doyu; M Li; T Yasuda; T Mitsuma
Journal:  Neurochem Res       Date:  1998-06       Impact factor: 3.996

3.  Prenatal ethanol effects on NGF level, NPY and ChAT immunoreactivity in mouse entorhinal cortex: a preliminary study.

Authors:  F Angelucci; M Fiore; C Cozzari; L Aloe
Journal:  Neurotoxicol Teratol       Date:  1999 Jul-Aug       Impact factor: 3.763

4.  Cholecystokinin-8 protects central cholinergic neurons against fimbria-fornix lesion through the up-regulation of nerve growth factor synthesis.

Authors:  P Tirassa; L Aloe; C Stenfors; P Turrini; T Lundeberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Regenerative effect of human recombinant NGF on capsaicin-lesioned sensory neurons in the adult rat.

Authors:  R Schicho; G Skofitsch; J Donnerer
Journal:  Brain Res       Date:  1999-01-02       Impact factor: 3.252

6.  Capsaicin applied to peripheral nerve inhibits axoplasmic transport of substance P and somatostatin.

Authors:  R Gamse; U Petsche; F Lembeck; G Jancsò
Journal:  Brain Res       Date:  1982-05-13       Impact factor: 3.252

7.  Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group.

Authors:  S C Apfel; J A Kessler; B T Adornato; W J Litchy; C Sanders; C A Rask
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

8.  Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor.

Authors:  J Scott; M Selby; M Urdea; M Quiroga; G I Bell; W J Rutter
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

9.  Putrescine-modified nerve growth factor: bioactivity, plasma pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution.

Authors:  J F Poduslo; G L Curran; J S Gill
Journal:  J Neurochem       Date:  1998-10       Impact factor: 5.372

10.  Rapid development of tolerance to the behavioural actions of cholecystokinin.

Authors:  J N Crawley; M C Beinfeld
Journal:  Nature       Date:  1983-04-21       Impact factor: 49.962

View more
  3 in total

1.  Effect of cholecystokinin on experimental neuronal aging.

Authors:  Xiao-Jiang Sun; Qin-Chi Lu; Yan Cai
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

2.  Effect of Cholecystokinin-8 (CCK-8) on Blood Pressure and Blood Content of Calcitonin-Gene-Related Peptide (CGRP) in Rats with Hypertension Caused by Fructose or Inhibition of Nitric Oxide Synthesis.

Authors:  Z S Tolochko; V K Spiridonov
Journal:  Bull Exp Biol Med       Date:  2021-10-07       Impact factor: 0.804

3.  Increased nerve growth factor signaling in sensory neurons of early diabetic rats is corrected by electroacupuncture.

Authors:  Stefania Lucia Nori; Maria Luisa Rocco; Fulvio Florenzano; Maria Teresa Ciotti; Luigi Aloe; Luigi Manni
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-21       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.